Objective: To detect the expression of SMG-1, ATM and P53 in laryngeal squamous cell carcinoma (LSCC) and their correlation with the clinicopathological features and outcomes of the patients.
Methods: Sixty-three specimens of surgically resected LSCC tissues and 30 specimens of adjacent normal tissue were examined for the expressions of ATM, SMG-1 and P53 using immunohistochemistry. The correlation of ATM, SMG-1 and P53 expressions with the clinicopathological factors and their interactions were analyzed.
Results: The positive expression rates of SMG-1, ATM and P53 in LSCC were 36.5% (23/63) , 41.3% (26/63) and 57.1% (36/63) respectively, significantly different from those in the adjacent tissue (73.3%, 83.3% and 20.0%, respectively; P<0.05). The expression of SMG-1 in LSCC was positively correlated with the pathological grade and T stage of the tumors (P<0.05), and ATM and P53 were not related to the clinicopathological factors (P>0.05). The 5-year survival rate of patients negative for SMG-1 expression was significantly higher than that of SMG-1-positive patients (P<0.05). The expression of SMG-1 was negatively correlated with that of P53 (r=-0.476, P<0.01).
Conclusion: SMG-1, ATM and P53 are closely related to the occurrence of LSCC. SMG-1 expression is an important factor associated with the clinicopathological features and prognosis of LSCC patients, and may play an important role in the development of LSCC by regulating P53 expression.